Comparison O
with O
_RARE_ I-GENE
_RARE_ I-GENE
and O
5 I-GENE
- I-GENE
_RARE_ I-GENE

_RARE_ O
aspects O
of O
neonatal O
hyperbilirubinemia O
. O

When O
CSF O
_RARE_ O
HCO3 O
_RARE_ O
is O
shown O
_RARE_ O
a O
function O
of O
CSF O
PCO2 O
the O
data O
of O
K O
- O
depleted O
rats O
are O
_RARE_ O
longer O
_RARE_ O
when O
compared O
to O
controls O
but O
still O
have O
a O
significantly O
greater O
slope O
( O
1 O
. O
21 O
+/- O
_RARE_ O
. O
_RARE_ O
_RARE_ O
. O

_RARE_ O
thus O
appears O
to O
be O
an O
effective O
_RARE_ O
drug O
with O
the O
_RARE_ O
dose O
_RARE_ O
use O
in O
_RARE_ O
practice O
being O
_RARE_ O
mg O
_RARE_ O
night O
. O

_RARE_ O
blocking O
agents O
. O

When O
_RARE_ O
CO2 O
removal O
_RARE_ O
CO2 O
production O
( O
_RARE_ O
_RARE_ O
alveolar O
ventilation O
almost O
_RARE_ O
. O

Intravenous O
administration O
( O
_RARE_ O
mg O
/ O
kg O
) O
of O
_RARE_ I-GENE
anhydrase I-GENE
_RARE_ O
( O
_RARE_ O
, O
_RARE_ O
, O
_RARE_ O
, O
_RARE_ O
) O
_RARE_ O
an O
early O
important O
rise O
of O
cortical O
p O
_RARE_ O
, O
which O
is O
not O
dependent O
on O
increase O
of O
p O
_RARE_ O
and O
p O
CO2 O
and O
decrease O
of O
pH O
in O
arterial O
_RARE_ O
. O

_RARE_ O
study O
of O
_RARE_ O
in O
the O
rat O
and O
_RARE_ O
. O

_RARE_ O
polyps O
should O
be O
removed O
_RARE_ O
_RARE_ O
possible O
. O

The O
_RARE_ O
HMG I-GENE
dosage O
regimen O
was O
found O
to O
offer O
_RARE_ O
advantages O
when O
compared O
with O
our O
standard O
daily O
dosage O
regimen O
